FrancophonIA/ELRC3.0 huggingface dataset:
English: The dose should therefore be adjusted, using an oral solution presentation of lamivudine for patients whose creatinine clearance falls below 30 ml/min (see tables).
Croatian: Stoga je potrebna prilagodba doze primjenom oralne otopine lamivudina u bolesnika s klirensom kreatinina manjim od 30 ml/min (vidjeti tablice).
English: Liver disease: If lamivudine is being used concomitantly for the treatment of HIV and HBV, additional information relating to the use of lamivudine in the treatment of hepatitis B infection is available in the lamivudine 100 mg SmPC.
Croatian: Bolest jetre: Ako se lamivudin istodobno koristi za liječenje HIV i HBV infekcija, dodatne informacije o primjeni lamivudina u liječenju hepatitisa B dostupne su u sažetku opisa svojstava lijeka za lamivudin 100 mg.
English: A small amount of the ingredients in Lamivudine Teva Pharma B.V. can also pass into your breast milk.
Croatian: Mala količina sastojaka lijeka Lamivudin Teva Pharma B.V. također može prijeći u majčino mlijeko.
English: More cases of resistance were detected among patients who had received lamivudine solution, in combination with other antiretroviral solutions, compared with those who received similar doses of tablet formulation.
Croatian: Otkriveno je više slučajeva rezistencije među bolesnicima koji su primali oralnu otopinu lamivudina u kombinaciji s drugim antiretrovirusnim lijekovima u obliku otopine u odnosu na one koji su primali slične doze u obliku tableta.
English: In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
Croatian: Ako bolesnik istodobno prima neki protuvirusni lijek za liječenje hepatitisa B ili C, treba proučiti odgovarajuće informacije i za te lijekove.
English: In 60 healthy adult volunteers, lamivudine 300 mg once daily has been demonstrated to be pharmacokinetically equivalent at steady-state to lamivudine 150 mg twice daily with respect to intracellular triphosphate AUC24 and Cmax.
Croatian: U 60 odraslih zdravih dobrovoljaca dokazano je da je farmakokinetika lamivudina u stanju ravnoteže, u dozi od 300 mg jedanput na dan, ekvivalentna lamivudinu u dozi 150 mg dvaput na dan s obzirom na AUC24 i Cmax intracelularnog trifosfata.
English: In PENTA 15 study, the geometric mean plasma lamivudine AUC(0-24) (95% CI) of the four subjects under 12 months of age who switch from a twice daily to a once daily regimen (see section 5.1) are 10.31 (6.26, 17.0) µg•h/mL in the once-daily dosing and 9.24 (4.66, 18.3) µg•h/mL in the twice-daily dosing.
Croatian: U ispitivanju PENTA 15, geometrijska srednja vrijednost AUC(0-24) lamivudina u plazmi (95% CI) u četiri ispitanika mlađa od 12 mjeseci koja su s režima primjene dvaput na dan prešla na režim primjene jedanput na dan (vidjeti dio 5.1) iznosila je 10,31 (6,26; 17,0) µg.h/ml uz doziranje jedanput na dan te 9,24 (4,66; 18,3) µg.h/ml uz doziranje dvaput na dan.
English: Tablet containers
Croatian: Spremnici za tablete
English: Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40% increase in lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did not interact.
Croatian: Zbog djelovanja komponente trimetoprima, primjena trimetoprim/sulfametoksazola u dozi od 160 mg/800 mg uzrokuje 40%-tni porast izloženosti lamivudinu; nema interakcija sa sulfametoksazolom.
English: It is metabolised intracellularly to the active moiety, lamivudine 5'-triphosphate.
Croatian: Lamivudin se intracelulamo metabolizira u aktivni lamivudin 5'-trifosfat.
English: Lamivudine Teva Pharma B.V. can be taken with or without food.
Croatian: Lamivudin Teva Pharma B.V. može se uzimati s hranom ili bez hrane.
English: Based on the assumption that creatinine clearance and lamivudine clearance are correlated similarly in children as in adults it is recommended that the dosage in children with renal impairment be reduced according to their creatinine clearance by the same proportion as in adults.
Croatian: Pod pretpostavkom da klirens kreatinina i klirens lamivudina u djece koreliraju s vrijednostima u odraslih; preporučuje se dozu lijeka u djece s oštećenjem bubrega smanjiti shodno njihovom klirensu kreatinina, a proporcionalno smanjenju doze u odraslih.
English: Following oral administration lamivudine was excreted in breast milk at similar concentrations to those found in serum.
Croatian: Nakon oralne primjene lamivudin se izlučuje u majčinom mlijeku u koncentracijama sličnima onima izmjerenima u serumu.
English: Based on these data, no dose adjustment is necessary in patients with moderate or severe hepatic impairment unless accompanied by renal impairment.
Croatian: Temeljem tih podataka, dozu nije potrebno prilagoditi u bolesnika s umjerenim do teškim oštećenjem jetre osim ako istovremeno nije prisutno oštećenje bubrega.
English: The abacavir + lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of <80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (<200 c/mL, <400 c/mL, <1000 c/mL), which all fell well within this non-inferiority margin.
Croatian: Prema unaprijed određenoj granici neinferiornosti od -12%, pokazalo se da je skupina koja je primala abakavir + lamivudin jedanput na dan bila neinferiorna skupini koja je primala te lijekove dvaput na dan, s obzirom na primarnu mjeru ishoda od <80 kopija/ml u 48. tjednu, ali i u 96. tjednu (sekundarna mjera ishoda), kao i sve druge ispitivane granične vrijednosti (<200 kopija/ml, <400 kopija/ml, <1000 kopija/ml), koje su se sve nalazile značajno unutar spomenute granice neinferiornosti.
English: -4.8% (95% CI -11.5% to +1.9%), p=0.16 Week 48
Croatian: -4,8% (95% CI -11,5% do +1,9%), p=0,16
English: Mitochondrial dysfunction: Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Croatian: Disfunkcija mitohondrija: Analozi nukleozida i nukleotida pokazali su u in vitro i in vivo uvjetima pokazali sposobnost uzrokovanja različitih stupnjeva mitohondrijskih oštećenja.
English: Moreover, Lamivudine Teva Pharma B.V. should not be taken with any other medicinal products containing lamivudine (see section 4.4).
Croatian: Osim toga, Lamivudin Teva Pharma B.V. se ne smije uzimati ni s jednim drugim lijekom koji sadrži lamivudin (vidjeti dio 4.4).
English: Rare: Rhabdomyolysis.
Croatian: Rijetko: rabdomioliza
English: -1.6% (95% CI -8.4% to +5.2%), p=0.65 Week 96
Croatian: -1,6% (95% CI -8,4% do +5,2%), p=0,65
English: • a low red blood cell count (anaemia) or low white blood cell count (neutropenia)
Croatian: • nizak broj crvenih krvnih stanica (anemija) ili bijelih krvnih stanica (neutropenija) • povišene vrijednosti jetrenih enzima.
English: 5 to <15
Croatian: 5 do < 15
English: Talk to your doctor if any of these apply to you.
Croatian: Obratite se svom liječniku ako se nešto od toga odnosi na Vas.
English: • other medicines containing lamivudine, (used to treat HIV infection or hepatitis B infection).
Croatian: • drugi lijekovi koji sadrže lamivudin (koji se primjenjuju za liječenje infekcija HIV-om ili hepatitisom B)
English: Children weighing ≥20 kg to <25 kg: The recommended dose is 225 mg daily.
Croatian: Djeca tjelesne težine od ≥ 20 kg do < 25 kg: Preporučena doza je 225 mg na dan.
English: If Lamivudine Teva Pharma B.V. is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis (see lamivudine 100 mg SmPC).
Croatian: Ako se ukida liječenje lijekom Lamivudin Teva Pharma B.V. u bolesnika zaraženih i HIV-om i HBVom, treba razmotriti periodičke jetrene probe i praćenje markera HBV replikacije jer prestanak uzimanja lamivudina može izazvati egzacerbaciju hepatitisa (vidjeti sažetak opisa svojstava lijeka za lamivudin 100 mg).
English: Tablet film coat: Hypromellose, titanium dioxide (E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide black (E172)
Croatian: Film ovojnica: hipromeloza, titaniijev dioksid (E171), makrogol, polisorbat 80, žuti željezov oksid
English: Alternatively, for patients who are unable to swallow tablets, the tablet(s) may be crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately (see section 5.2).
Croatian: Ako to nije moguće, za bolesnike koji ne mogu gutati tablete, tabletu se može zdrobiti i pomiješati s manjom količinom kašaste hrane ili tekućine te odmah progutati (vidjeti dio 5.2).
English: The therapy should be initiated by a physician experienced in the management of HIV infection.
Croatian: 4.2 Doziranje i način primjene Liječenje treba započeti liječnik s iskustvom u liječenju HIV infekcije.
English: Lamivudine has been widely used as a component of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (PIs, non-nucleoside reverse transcriptase inhibitors).
Croatian: Lamivudin se široko primjenjuje kao jedan od lijekova u kombiniranoj antiretrovirusnoj terapiji s drugim antiretrovirusnim lijekovima iste skupine (inhibitori reverzne transkriptaze nukleozida) ili drugih skupina (inhibitori proteaze, inhibitori reverzne transkriptaze nenukleozida).
English: Talk to your doctor or pharmacist before taking Lamivudine Teva Pharma B.V..
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Lamivudin Pharma B.V.
English: The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal clearance.
Croatian: Vjerojatnost metaboličkih interakcija je mala zbog ograničenog metabolizma i vezanja na bjelančevine u plazmi te gotovo potpuni bubrežni klirens.
English: Microcrystalline cellulose Sodium starch glycolate (Type A) Magnesium Stearate
Croatian: celuloza, mikrokristalična natrijev škroboglikolat (vrste A) magnezijev stearat
English: What Lamivudine Teva Pharma B.V. is and what it is used for
Croatian: Što je Lamivudin Teva Pharma B.V. i za što se koristi
English: At a therapeutic dose of 300 mg once daily, the mean (CV) steady-state Cmax, Cmin and 24h AUC are 2.0 µg/ml (26%), 0.04 µg/ml (34%) and 8.9 µg•h/ml (21%), respectively.
Croatian: Pri terapijskoj dozi od 300 mg jedanput na dan, srednji Cmax (u stanju dinamičke ravnoteže) iznosi 2,0 µg/ml (26%), Cmin iznosi 0,04 µg/ml (34%), a 24 satni AUC 8,9 µg.h/ml (21%).
English: Immune Reactivation Syndrome: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: Sindrom imunološke reaktivacije: U bolesnika zaraženih HIV-om koji u trenutku započinjanja kombinacijskog antiretrovirusnog liječenja imaju teški imunološki deficit, može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te izazvati ozbiljna klinička stanja ili pogoršanje simptoma.
English: Due to similarities, Lamivudine Teva Pharma B.V. should not be administered concomitantly with other cytidine analogues, such as emtricitabine.
Croatian: Lamivudin Teva Pharma B.V. se zbog sličnosti ne smije primjenjivati istodobno s drugim citidinskim analozima, poput emtricitabina.
English: Lamivudine Teva Pharma B.V. is not recommended for use as monotherapy.
Croatian: Lamivudin Teva Pharma B.V. ne preporučuje se koristiti u monoterapiji.
English: Based on data derived from a study in healthy volunteers, at a therapeutic dose of 150 mg twice daily, mean (CV) steady-state Cmax and Cmin of lamivudine in plasma are 1.2 µg/ml (24%) and 0.09 µg/ml (27%), respectively.
Croatian: Na temelju podataka ispitivanja na zdravim dobrovoljcima, pri terapijskoj dozi od 150 mg dvaput na dan, srednji Cmax (u stanju dinamičke ravnoteže) i Cmin lamivudina u plazmi iznose 1,2 µg/ml (24%), odnosno 0,09 µg/ml (27%).
English: Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Lamivudine Teva Pharma B.V..
Croatian: Ne zaboravite liječniku ili ljekarniku reći da ste počeli uzimati neki novi lijek za vrijeme terapije lijekom Lamivudin Teva Pharma B.V.
English: You need to know about important signs and symptoms to look out for while you are taking Lamivudine Teva Pharma B.V..
Croatian: Trebate biti upoznati s važnim znakovima i simptomima dok uzimate Lamivudin Teva Pharma B.V.
English: Renal impairment: In patients with moderate to severe renal impairment, the terminal plasma half-life of lamivudine is increased due to decreased clearance; therefore the dose should be adjusted (see section 4.2).
Croatian: Oštećenje bubrežne funkcije: U bolesnika s umjerenim do teškim oštećenjem funkcije bubrega poluvrijeme izlučivanja lamivudina u plazmi produljeno je zbog smanjenog kIirensa te je stoga potrebno prilagoditi dozu (vidjeti dio 4.2.).
English: Dosing recommendations - Children aged at least 3 months and weighing less than 25 kg: Creatinine clearance (ml/min) First dose
Croatian: Preporuke za doziranje u djece u dobi od najmanje 3 mjeseca, čija je tjelesna težina manja od 25 kg: Klirens kreatinina (ml/min)
English: Tablet core: Microcrystalline cellulose, sodium starch glycolate, magnesium stearate.
Croatian: Jezgra tablete: mikrokristalična celuloza, natrijev škroboglikolat, magnezijev stearat.
English: Children weighing 14 kg to <20 kg: The recommended dose is 150 mg daily.
Croatian: Djeca tjelesne težine od 14 kg do < 20 kg: Preporučena doza je 150 mg na dan.
English: Drug Interactions: Lamivudine Teva Pharma B.V. should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).
Croatian: Interakcije s drugim lijekovima: Lamivudin Teva Pharma B.V. ne smije se primjenjivati s drugim lijekovima koji sadrže lamivudin ili emtricitabin (vidjeti dio 4.5).
English: Summary of Stead-State Plasma Lamivudine AUC (0-24) (µg•h/mL) and Statistical Comparisons for Once and Twice-Daily Oral Administration Across Studies
Croatian: Sažetak plazmatske vrijednosti AUC(0-24) (µg.h/ml) lamivudina u stanju dinamičke ravnoteže i statističke usporedbe peroralne primjene jedanput na dan u odnosu na primjenu dvaput na dan u svim ispitivanjima
English: Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC∞) and 28%, 52%, and 55% in the Cmax of lamivudine in adults.
Croatian: Istodobna primjena otopine sorbitola (3,2 g, 10,2 g, 13,4 g) s jednom dozom od 300 mg oralne otopine lamivudina rezultirala je o dozi ovisnim smanjenjem od 14%, 32% i 36% u izloženosti lamivudinu
English: For patients co-infected with hepatitis who are being treated with lamivudine and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.
Croatian: Za bolesnice s istodobnom infekcijom virusom hepatitisa koje su liječene lamivudinom te su u međuvremenu zatrudnjele mora se svakako uzeti u obzir mogućnost rekurentne pojave hepatitisa po obustavi liječenja lamivudinom.
English: Week 0 (after 36 weeks on treatment) Any solution regimen at any time All tablet based regimen throughouts Week 96
Croatian: 0. tjedan (nakon 36 tjedana liječenja) Bilo koja otopina u bilo kojem trenutku 14/26 (54) Samo tablete tijekom cjelokupnog liječenja
English: Dosing recommendations - Adults, adolescents and children (weighing at least 25 kg):
Croatian: Doziranje Odrasli, adolescenti i djeca (tjelesne težine najmanje 25 kg)
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/596/014
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/596/014
English: A transplacental genotoxicity study conducted in monkeys compared zidovudine alone with the combination of zidovudine and lamivudine at human-equivalent exposures.
Croatian: U ispitivanjima transplacentalne genotoksičnosti na majmunima uspoređivan je zidovudin sam i u kombinaciji s lamivudinom i to u dozama izloženosti koje su bile ekvivalentne humanim dozama.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/596/007
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/596/007
English: Uncommon: Neutropenia and anaemia (both occasionally severe), thrombocytopenia.
Croatian: Manje često: neutropenija i anemija (ponekad teške), trombocitopenija.
English: Lamivudine 8 mg/kg OnceDaily Dosing Geometric Mean (95% Cl)
Croatian: Lamivudin 8 mg/kg jedanput na dan - geometrijska srednja vrijednost (95% Cl)
English: Other possible side effects of combination therapy for HIV Combination therapy including Lamivudine Teva Pharma B.V. may cause other conditions to develop during HIV treatment.
Croatian: Druge moguće nuspojave kombinirane terapije za HIV Kombinirana terapija koja sadrži Lamivudin Teva Pharma B.V. može uzrokovati razvoj drugih bolesti i stanja tijekom liječenja HIV-a.
English: Children weighing at least 20 kg and less than 25 kg The usual dose of Lamivudine Teva Pharma B.V. is 225 mg a day.
Croatian: Djeca tjelesne težine najmanje 20 kg, ali manje od 25 kg Uobičajena doza lijeka Lamivudin Teva Pharma B.V. je 225 mg na dan.
English: Children receiving lamivudine oral solution concomitantly with other antiretroviral oral solutions in clinical trials developed viral resistance more frequently than children receiving tablets (see the description of the clinical experience in paediatric population (ARROW study) and section 5.2).
Croatian: U djece koja su u kliničkim ispitivanjima primala oralnu otopinu lamivudina istodobno s drugim antiretrovirusnim lijekovima u obliku oralne otopine virusna rezistencija razvila se češće nego u djece koja su primala tablete (vidjeti opis kliničkog iskustva u pedijatrijskoj populaciji (ispitivanje
English: Not everyone responds to treatment with Lamivudine Teva Pharma B.V. in the same way.
Croatian: Ne reagiraju svi jednako na liječenje lijekom Lamivudin Teva Pharma B.V.
English: Lamivudine Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection in adults and children.
Croatian: Lamivudin Teva Pharma B.V. primjenjuje se za liječenje infekcija HIV-om (virusom humane imunodeficijencije) u odraslih i djece.
English: An oral solution is also available for the treatment of children over 3 months of age, or for people who need a lower dose than usual, or who cannot take tablets.
Croatian: Za liječenje djece u dobi od više od 3 mjeseca ili ljudi koji trebaju manju dozu od uobičajene ili koji ne mogu uzimati tablete dostupna je oralna otopina.
English: • emtricitabine (used to treat HIV infection).
Croatian: • emtricitabin (koji se primjenjuju za liječenje infekcija HIV-om)
English: White opaque HDPE tablet containers with white opaque polyethylene child resistant screw cap with induction seal.
Croatian: Bijeli neprozirni spremnici od polietilena visoke gustoće s bijelim neprozirnim polietilenskim sigurnosnim zatvaračem za djecu s navojem i zatvoreni zalijepljenom zaštitnom folijom.
English: If you forget to take Lamivudine Teva Pharma B.V.
Croatian: Ako ste zaboravili uzeti Lamivudin Teva Pharma B.V.
English: However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary (see section 4.2).
Croatian: Međutim prilagodba doze nije potrebna osim ako bolesnik nema i oštećenu funkciju bubrega (vidjeti dio 4.2.).
English: Absorption differences have been observed between adult and paediatric populations (see “Special populations”).
Croatian: Između odrasle i pedijatrijske populacije primijećene su razlike u apsorpciji
English: Tablet film coat Hypromellose 3cP Hypromellose 6cP Titanium dioxide Macrogol 400
Croatian: Film-ovojnica tablete: hipromeloza 3cP hipromeloza 6cP titanijev dioksid makrogol 400 polisorbat 80 željezov oksid, žuti željezov oksid, crni
English: Lamivudine Teva Pharma B.V. is a type of medicine known as an antiretroviral.
Croatian: Lamivudin Teva Pharma B.V. je antiretrovirusni lijek.
English: This may be administered as either 150 mg twice daily or 300 mg once daily (see section 4.4).
Croatian: Preporučena doza lamivudina je 300 mg na dan, primijenjeno ili kao 150 mg dvaput na dan ili 300 mg jedanput na dan (vidjeti dio 4.4).
English: Plasma HIV-1 RNA <80 c/mL Risk difference (once daily-twice daily)
Croatian: HIV-1 RNK u plazmi <80 kopija/ml Razlika u riziku (jedanput na dan-dvaput na dan)
English: Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Grey, diamond shaped, biconvex film-coated tablet with approx. 18.0 mm length and 8.0 mm widthengraved with “L 300” on one side and plain on the other
Croatian: Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete Siva, bikonveksna, filmom obložena tableta u obliku dijamanta, oko 18,0 mm duga i 8,0 mm široka, s utisnutom oznakom “L 300” na jednoj strani i bez oznake na drugoj strani.
English: Paediatric population: a randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients.
Croatian: Pedijatrijska populacija: u sklopu randomiziranog, multicentričnog, kontroliranog ispitivanja s pedijatrijskim bolesnicima zaraženima HIV-om provedena je randomizirana usporedba režima primjene abakavira i lamivudina jedanput na dan u odnosu na režim primjene dvaput na dan.
English: Lamivudine Teva Pharma B.V. 300 mg film-coated tablets EU/1/09/596/008 20 tablets (blister) EU/1/09/596/009 30 tablets (blister) EU/1/09/596/010 60 tablets (blister) EU/1/09/596/011 90 tablets (blister) EU/1/09/596/012 100 tablets (blister) EU/1/09/596/013 500 tablets (blister) EU/1/09/596/014 30 tablets (bottle) EU/1/09/596/016 80 tablets(blister)
Croatian: Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete EU/1/09/596/008 20 tableta (blister) EU/1/09/596/009 30 tableta (blister) EU/1/09/596/010 60 tableta (blister) EU/1/09/596/011 90 tableta (blister) EU/1/09/596/012 100 tableta (blister) EU/1/09/596/013 500 tableta (blister) EU/1/09/596/014 30 tableta (boca) EU/1/09/596/016 80 tableta (blister)
English: • cladribine (used to treat hairy cell leukaemia).
Croatian: • kladribin (koji se primjenjuje za liječenje leukemije vlasastih stanica).
English: Hepatic impairment: Data obtained in patients with moderate to severe hepatic impairment shows that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.
Croatian: Podaci u bolesnika s umjerenim do teškim oštećenjem jetre pokazuju da oštećenje jetre ne utječe značajno na farmakokinetiku lamivudina.
English: Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
Croatian: Lamivudin Teva Pharma B.V. je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih osoba i djece zaraženih virusom humane imunodeficijencije (HIV).
English: Other medicines and Lamivudine Teva Pharma B.V.
Croatian: Drugi lijekovi i Lamivudin Teva Pharma B.V.
English: These medicines should not be used with Lamivudine Teva Pharma B.V.:
Croatian: Sljedeći se lijekovi ne smiju primjenjivati istovremeno s lijekom Lamivudin Teva Pharma B.V.:
English: No studies on the effects on the ability to drive and use machines have been performed.
Croatian: 4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Nisu provedena ispitivanja o utjecaju lamivudina na sposobnost upravljanja vozilima i rada sa strojevima.
English: Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 60 tablets.
Croatian: Lamivudin Teva Pharma B.V. dostupan je u aluminijskim blisterima s 20, 30, 60, 80, 90, 100 i 500
English: INFORMATION IN BRAILLE Lamivudine Teva Pharma B.V. 300 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU Lamivudin Teva Pharma B.V. 300 mg